PT  - JOURNAL ARTICLE
AU  - Tristan W. Dorey
AU  - Matthias Walter
AU  - Andrei V Krassioukov
TI  - Reduced Reflex Autonomic Responses following Intradetrusor OnabotulinumtoxinA Injections: A pre/post study in Individuals with Cervical and Upper Thoracic Spinal Cord Injury
AID  - 10.1101/2021.04.24.21256011
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.24.21256011
4099  - http://medrxiv.org/content/early/2021/04/26/2021.04.24.21256011.short
4100  - http://medrxiv.org/content/early/2021/04/26/2021.04.24.21256011.full
AB  - Importance Urodynamic studies (UDS) can provoke autonomic dysreflexia (AD) in individuals with spinal cord injury (SCI) at and above the sixth thoracic (T6) spinal segment potentially leading to profound vagally mediated heart rate reductions. Intradetrusor onabotulinumtoxinA injections have been shown to reduce AD events during UDS in this cohort but evidence is lacking whether this treatment can improve reflex autonomic responses.Objective To assess the effects of intradetrusor onabotulinumtoxinA injections on heart rate variability (HRV) responses to UDS in individuals, 18-65 years of age, with chronic (>1-year) SCI at or above T6 with confirmed neurogenic detrusor overactivity and AD during UDS.Design, Setting, and Participants This cohort study used participants from our recent prospective phase IV clinical trial. Individuals were screened at an academic medical centre between November 2014 and December 2019. After enrollment, participants underwent UDS prior to (i.e., baseline) and one month after intradetrusor onabotulinumtoxinA injections (post-treatment).Interventions OnabotulinumtoxinA (200 U) was injected into the detrusor muscle at 20 sites (10 U/site).Main Outcomes and Measures Continuous electrocardiogram (ECG) and blood pressure (BP) recordings were used to assess RR-interval, time and frequency domain metrics of HRV (a surrogate marker of autonomic nervous system activity), and AD pre- and post-intervention.Results A total of 19 participants with SCI (5 women; mean [SD] age 42 [8.3] years) with complete ECG and BP data sets were suitable for autonomic analysis. During baseline UDS, an increase in RR-interval (adjusted mean difference, -0.08; 95% CI, -0.14 to -0.03; P=0.002) as well as time and frequency domain metrics of HRV were detected. Vagally mediated increases in high frequency (HF) power during UDS were larger in participants with cervical SCI compared to upper thoracic SCI (adjusted mean difference, 20.3; 95% CI, 3.3 to 37.2; P=0.013). Intradetrusor onabotulinumtoxinA injections significantly reduced time domain metrics of HRV and HF power (adjusted mean difference, 9.1; 95% CI, 3.1 to 15.1, P<0.01) responses to UDS across all participants.Conclusions and Relevance Changes in HRV during UDS could be a potential indicator of improved autonomic cardiovascular function following interventions such as intradetrusor onabotulinumtoxinA injections.Trial Registration ClinicalTrials.gov Identifier: NCT02298660Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02298660Funding StatementTristan W. Dorey (Canadian Institutes for Health Research Doctoral Research Award), Matthias Walter (Postdoctoral Research Trainee Award from the Michael Smith Foundation for Health Research in partnership with the Rick Hansen Foundation under Grant number 17110 and Vancouver Coastal Health Research Institute Rising Start Award), Andrei V. Krassioukov (Praxis Spinal Cord Institute, i.e., formerly Rick Hansen Institute, Grant number G2013-09 and Allergan Inc. for providing study drug Botox in-kind and a publication grant PG-2020-10932). Dr. Krassioukov also holds the Endowed Chair in Rehabilitation Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This prospective phase IV clinical trial using a pre-post study design was approved by the University of British Columbia Clinical Research Ethics Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available from the corresponding author on reasonable request.